Oxidative Phosphorylation

Oxidative Phosphorylation is the specific mitochondrial inner-membrane process by which the electron transport chain complexes and ATP synthase couple the oxidation of reduced electron carriers, generated from glucose, glutamine, and fatty acid metabolism, to the phosphorylation of ADP into ATP, providing the biochemical machinery whose activity level and regulation determine a given cancer cell or cancer cell subpopulation's degree of dependence on oxidative versus glycolytic energy metabolism. Where mitochondrial metabolism addresses the broader range of mitochondrial functions including biosynthesis and signaling, and aerobic glycolysis addresses the glycolytic alternative pathway, this topic addresses the specific electron transport chain biochemistry and its direct pharmacological targeting in cancer.

The Electron Transport Chain Complex Architecture

Oxidative phosphorylation proceeds through a series of four multi-subunit protein complexes embedded in the inner mitochondrial membrane, followed by ATP synthase as a fifth functional complex:

Complex I (NADH dehydrogenase) and Complex II (succinate dehydrogenase, also a direct TCA cycle enzyme) accept electrons from NADH and FADH2 respectively, passing them through the mobile carrier ubiquinone to Complex III (cytochrome bc1 complex) and subsequently, via cytochrome c, to Complex IV (cytochrome c oxidase), which reduces molecular oxygen to water as the terminal electron acceptor. Electron transfer through Complexes I, III, and IV is coupled to proton pumping across the inner mitochondrial membrane, establishing an electrochemical proton gradient that ATP synthase (Complex V) subsequently uses to drive ATP production as protons flow back down this gradient through the enzyme's rotary catalytic mechanism.

Retained Complex Assembly and Function in Cancer

Consistent with the modern understanding that cancer cell mitochondria are generally structurally and functionally intact rather than damaged, electron transport chain complexes in most cancer cells remain properly assembled and enzymatically active, capable of supporting substantial oxidative ATP production when required, though relative expression and activity levels of individual complexes can be modulated by oncogenic signaling and hypoxic conditions, contributing to the variable balance between glycolytic and oxidative metabolism observed across different cancer cell states and subpopulations.

Diagram: Electron Transport Chain and Coupled ATP Synthesis

Selective Dependence and Therapeutic Targeting

Because specific therapy-relevant cancer cell subpopulations (cancer stem cells, drug-tolerant persister cells) display selective dependence on oxidative phosphorylation rather than glycolysis, the electron transport chain has become a specific pharmacological target of interest:

1. Complex I Inhibitors — Agents such as IACS-010759, developed specifically as Complex I inhibitors, have demonstrated selective efficacy against oxidative phosphorylation-dependent cancer cell populations in preclinical studies, exploiting the differential metabolic dependence of these subpopulations relative to bulk, more glycolytic tumor tissue.
2. Biguanides (Metformin and Related Compounds) — Originally developed as antidiabetic agents, biguanides act in part through mild Complex I inhibition, and epidemiological and preclinical evidence of anti-cancer activity associated with metformin use has motivated clinical investigation of biguanides as adjunctive cancer therapy, particularly relevant to targeting oxidative phosphorylation-dependent subpopulations.
3. Combination Strategies — Because bulk tumor tissue and oxidative phosphorylation-dependent subpopulations coexist within the same tumor, combination approaches pairing electron transport chain inhibition with glycolysis-targeting agents have been proposed as a means of simultaneously addressing both major metabolic dependencies present within a heterogeneous tumor, rather than allowing a metabolically flexible tumor to compensate by shifting toward whichever pathway remains untargeted.

Metabolic Flexibility as a Resistance Mechanism to OXPHOS Targeting

A significant challenge for oxidative phosphorylation-targeted therapy is the metabolic flexibility of many cancer cells, which can shift toward increased glycolytic flux to compensate for pharmacological oxidative phosphorylation inhibition, potentially limiting the durability of single-agent electron transport chain-targeted treatment and reinforcing the rationale for combination strategies that simultaneously constrain both major energy-generating pathways.

Experimental Assessment

Oxidative phosphorylation activity is directly measured using extracellular flux analysis (Seahorse-type assays) to quantify oxygen consumption rate under basal and maximal (uncoupled) conditions, individual electron transport chain complex activity assays performed on isolated mitochondria or permeabilized cells, and genetic or pharmacological complex-specific inhibition combined with viability and functional assays applied to sorted cancer stem cell, persister, or bulk tumor cell populations to establish differential dependence and guide rational combination therapy design.